Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 1205-1211

  Hrstka, Roman ^a   Beranek, Michal ^b   Klocova, Katerina ^a   Nenutil, Rudolf ^a   Vojtesek, Borivoj ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

PIN3 Ins 16bp; PIN6 G13494A; Polymorphism; R72P; TP53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; INTRON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; GENE FREQUENCY; HUMANS; IMMUNOENZYME TECHNIQUES; INTRONS; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 70449346871     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000556     Document Type: Article

References (31)

1. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
2. Jin S and Levine AJ: The p53 functional circuit. J Cell Sci 114: 4139-4140, 2001.
3. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
4. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
5. Alsner J, Yilmaz M, Guldberg P, Hansen LL and Overgaard J: Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 6: 3923-3931, 2000.
6. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614, 2002.
7. Harris N, Brill E, Shohat O, et al: Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6: 4650-4656, 1986.
8. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J and Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7: 961-963, 1987.
9. Felley-Bosco E, Weston A, Cawley HM, Bennett WP and Harris CC: Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 53: 752-759, 1993.
10. Beckman G, Birgander R, Sjalander A, et al: Is p53 polymorphism maintained by natural selection? Hum Hered 44: 266-270, 1994.
11. Baptiste N, Friedlander P, Chen X and Prives C: The proline-rich domain of p53 is required for cooperation with antineoplastic agents to promote apoptosis of tumor cells. Oncogene 21: 9-21, 2002.
12. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
13. Marin MC, Jost CA, Brooks LA, et al: A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47-54, 2000.
14. Lazar V, Hazard F, Bertin F, Janin N, Bellet D and Bressac B: Simple sequence repeat polymorphism within the p53 gene. Oncogene 8: 1703-1705, 1993.
15. McDaniel T, Carbone D, Takahashi T, et al: The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res 19: 4796, 1991.
16. Chumakov PM and Jenkins JR: BstNI/NciI polymorphism of the human p53 gene (TP53). Nucleic Acids Res 19: 6969, 1991.
17. Elston CW and Elis IO: Assessment of histological grade. In: The Breast. Elston CW and Elis IO (eds). Churchill Livingstone, Edinburgh, pp365-384, 1998.
18. Zhu ZZ, Cong WM, Liu SF, et al: A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett 229: 77-83, 2005.
19. Pharoah PD, Day NE and Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80: 1968-1973, 1999.
20. Hrstka R, Coates PJ and Vojtesek B: Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 13: 440-453, 2009.
21. Tommiska J, Eerola H, Heinonen M, et al: Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11: 5098-5103, 2005.
22. Khadang B, Fattahi MJ, Talei A, Dehaghani AS and Ghaderi A: Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173: 38-42, 2007.
23. Costa S, Pinto D, Pereira D, et al: Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8: 32, 2008.
24. Buyru N, Tigli H and Dalay N: P53 codon 72 polymorphism in breast cancer. Oncol Rep 10: 711-714, 2003.
25. Papadakis EN, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392, 2000.
26. Soussi T and Wiman KG: Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303-312, 2007.
27. Boldrini L, Gisfredi S, Ursino S, et al: Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest 26: 168-172, 2008.
28. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R and Runnebaum IB: p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 18: 2095-2099, 1998.
29. Mahasneh AA and Abdel-Hafiz SS: Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 25: 1568-1573, 2004.
30. Sjalander A, Birgander R, Hallmans G, et al: p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17: 1313-1316, 1996.
31. Gemignani F, Moreno V, Landi S, et al: A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 23: 1954-1956, 2004.